GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases
GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warni...
Safety Radar
MHRA safety updates, clinically surfaced.
Drug safety updates, recalls and regulatory warnings from MHRA, organised for rapid clinical review and specialty follow-up.
58 safety updates
02 Sep 2026 latest update
MHRA source-linked
Latest Safety Update
Filters should be used during the administration of Parenteral Nutrition for patients in all care settings
Parenteral nutrition must be administered through appropriate filters across all care settings to prevent particulate matter embolism, which can be fatal Non-filtered PN administration represents a significant patient safety risk and has been linked…
02 Sep 2026 · Read clinical summary
Drug Safety
MHRA sourceRecent MHRA Updates
Isotretinoin – changes to prescribing guidance and additional risk minimisation measures
The Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin, following a review of the impact of the measures implemented in 2023.…
Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs
The MHRA has reviewed the warnings regarding addiction, dependence, withdrawal, and tolerance for gabapentin, pregabalin, benzodiazepines, and z-drugs. The findings (detailed in the Public Assessment Report) were that…
Rybelsus ® (semaglutide tablets): transition to new formulation and risk of medication error
Rybelsus ® (semaglutide tablets): transition to new formulation and risk of med...
Mesalazine and idiopathic intracranial hypertension
Idiopathic intracranial hypertension (IIH) has been very rarely reported in patients treated with mesalazine. Following a recent review, warnings for IIH are being added to the product information…
Isotretinoin – updates to prescribing guidance and survey of services
The Commission on Human Medicines (CHM) has endorsed changes to isotretinoin prescribing guidance. In addition, CHM is seeking further information from dermatology services who prescribe isotretinoin to inform…
#MedSafetyWeek (3-9 November 2025): A call to action to improve patient safety
The annual #MedSafetyWeek campaign takes place from 3 to 9 November 2025. This year’s campaign theme is ‘we can all help make medicines safer.’ This update is best…
Paracetamol and pregnancy – reminder that taking paracetamol during pregnancy remains safe
Patients should be reminded and reassured that there is no evidence that taking paracetamol during pregnancy causes autism in children. Paracetamol is recommended as the first-choice pain reliever…
Abrysvo▼ (Pfizer RSV vaccine) and Arexvy▼ (GSK RSV vaccine): be alert to a small risk of Guillain-Barré syndrome following vaccination in older adults
There is a small increase in the risk of Guillain-Barré syndrome following vaccination with Abrysvo (Pfizer respiratory syncytial virus (RSV) vaccine) and Arexvy (GSK RSV vaccine) in adults…
Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell▼): updated safety and educational materials to support patient discussion on reproductive risks
Updated safety and educational materials are now available to support the implementation of the regulatory measures announced in the November 2023 National Patient Safety Alert and the September…
Thiopurines and intrahepatic cholestasis of pregnancy
Thiopurines and intrahepatic cholestasis of pregnancy
Kaftrio▼ (Ivacaftor, tezacaftor, elexacaftor): risk of psychological side effects
Psychological side effects such as anxiety, low mood, sleep disturbance, poor concentration, and forgetfulness have been infrequently reported in people with cystic fibrosis treated with Kaftrio. Healthcare professionals…